Home > Companies > Orbona Pharma Ltd

Orbona Pharma Ltd

orbona.co.uk

Orbona Pharma Ltd is a privately held start up specialist pharmaceutical company dedicated to improving the lives’ of children with rare diseases. Established in late 2011 Orbona Pharma is developing two late stage drugs to treat a number of Orphan diseases. Between 50%-90% of medicines administered to children have not been developed for them (source: EMA and Eurodis) and often Medicines used are those for adults; administered to children by decreasing quantities based on weight, which can be extremely hazardous and is far from ideal. Orbona Pharma is working to address this. Orbona Pharma is working on two late stage drugs in oncology and immunology and is developing a pipeline of other candidates for development. Based in the UK, but with a network of experienced professionals in Europe, the US and elsewhere, Orbona is working hard to establish a global presence.

C-Suite On Deck

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Events

National Medtech & Biotech Summit 2024

Conference

2024 AAPS NATIONAL BIOTECHNOLOGY CONFERENCE

Conference

Related News

Pharmacy Market

LTS COMPLETES ITS ENTRY INTO LARGE MOLECULE DRUG DELIVERY WITH THE ACQUISITION OF THE SORREL WEARABLE INJECTION DEVICE BUSINESS

PRNewswire | June 09, 2023

LTS LOHMANN Therapie-Systeme AG ("LTS"), a leading pharmaceutical technology company that develops and manufactures innovative drug delivery systems such as Transdermal Patches ("TTS"), Oral Thin Films ("OTF") and Micro Array Patches ("MAP") has completed its acquisition of the Sorrel wearable injection device business ("Sorrel") with headquarters in Netanya, Israel, from Eitan Medical Ltd ("Eitan Medical"). Terms of the transacti...

PHARMACY MARKET, PHARMA TECH

CAPSIDA BIOTHERAPEUTICS AND ABBVIE ANNOUNCE EXPANSION OF COLLABORATION

Capsida Biotherapeutics | February 27, 2023

Capsida Biotherapeutics Inc., a fully integrated next-generation gene therapy platform company, and AbbVie, a pharmaceutical company dedicated to discovering and providing innovative medicines to address serious health issues, have recently announced an expanded strategic collaboration. The collaboration aims to develop genetic medicines for eye diseases with high unmet needs. Capsida's novel adeno-associated virus (AAV) engineering platform and manufacturing capability will...

Pharma Tech

GINKGO BIOWORKS AND CENTRIENT PHARMACEUTICAL ANNOUNCE EXPANSION OF PARTNERSHIP FOLLOWING SUCCESS OF INITIAL PROJECT TO BRING INNOVATION TO GENERIC API

PR Newswire | May 26, 2023

Centrient Pharmaceuticals ("Centrient"), the global business-to-business leader in sustainable antibiotics, next-generation statins and anti-fungals, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced they are expanding their existing partnership aimed at broadening Centrient's portfolio of environmentally friendly active pharmaceutical ingredients (APIs), following the success of previous work togethe...

Business Insights

ACULYS PHARMA AND SUSMED HAVE ENTERED INTO A CONTRACT TO CONDUCT THE WORLD'S FIRST CLINICAL TRIAL UTILIZING BLOCKCHAIN TECHNOLOGY

Aculys Pharma, Inc. | July 13, 2022

Aculys Pharma, Inc. a company focused on the development and commercialization of new innovative drugs in the fields of neurology and psychiatry, has entered into a contract with SUSMED, Inc., a company that promotes digital medicine to conduct the world's first1 corporate-sponsored clinical trial using blockchain technology. The clinical trial utilizing this blockchain technology, provided by SUSMED, will be conducted in collaboration with CMIC Co., Ltd., a pioneer in drug development suppo...

Pharmacy Market